Botox and Filler for GLP-1 Patients: What Allergan’s New HARMONY and HALO Data Show

Aesthetic Medicine News

Portland, OR · November 9, 2026

By Cosmetiq Medicine · 8 min read

Allergan Aesthetics released results on November 8, 2026 from two Phase 4 studies of Botox Cosmetic and hyaluronic acid filler in adults taking GLP-1 medications for weight loss, and patients in both reported large gains in how satisfied they were with their faces. Here is what the data show, what they leave out, and what it means if you are weighing injectables during a GLP-1 program in Portland or Vancouver, WA.

What did Allergan Aesthetics announce about GLP-1 patients?

On November 8, 2026, Allergan Aesthetics reported that adults on GLP-1 medications who received hyaluronic acid filler, with or without onabotulinumtoxinA (BOTOX Cosmetic), reported statistically significant gains in satisfaction with their facial appearance. The results come from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting in San Diego.

Allergan describes HARMONY IN DIVERSITY as the first study to evaluate a neurotoxin combined with hyaluronic acid injectables in people taking GLP-1 medications, according to the company announcement on PR Newswire. Trade outlet Personal Care Insights reported the results on November 9 and noted that the skincare industry is paying closer attention to people using GLP-1 drugs and the facial changes that can come with weight loss.

The release cites a 2026 review in the Aesthetic Surgery Journal Open Forum, Moradi and colleagues, for the point that people taking GLP-1 medications may experience facial changes, including loss of facial volume and changes in skin quality. Study investigator Joely Kaufman-Janette of the Skin Research Institute put the value plainly: having data specific to this population, she said, “gives us a clearer starting point for setting expectations.”

What do the HARMONY IN DIVERSITY and HALO numbers show?

In HARMONY IN DIVERSITY’s GLP-1 cohort, 30 adults received filler, onabotulinumtoxinA and a skincare regimen, and their FACE-Q satisfaction score rose 42.4 points 30 days after the toxin. In HALO’s interim analysis, 25 adults treated with filler across the face rose 39.6 points by month 3.

On side effects, Allergan reported that most treatment-related adverse events in the GLP-1 cohort were mild, nonserious and resolved without intervention, with no evidence of distant spread of toxin. Botox Cosmetic still carries the boxed warning on distant spread of toxin effect in its FDA prescribing information, which your injector reviews with you before any treatment.

What is FACE-Q, and what does a 40-point gain mean?

FACE-Q is a validated questionnaire in which patients rate their own appearance. Scores run from 0 to 100, with higher meaning more satisfied, so a gain of about 40 points means participants rated their faces much more favorably after treatment than before it.

The instrument was built from interviews with aesthetic patients and tested in published validation studies, including Klassen and colleagues in JAMA Dermatology. It measures how people feel about their appearance, not how much volume was restored or how long the result lasts. That distinction matters when you read the headline numbers.

The angle most coverage is missing: these patients were already on stable doses

Both studies enrolled adults on stable doses of GLP-1 medications. The results do not tell you how filler performs while someone is still increasing their dose or actively losing weight, which is exactly when many people first notice changes in their face.

Most headlines stopped at the satisfaction scores. Read the study descriptions in Allergan’s release and a few limits stand out:

• Stable doses, not active titration. Participants were on stable GLP-1 doses. The release does not report results for people mid-titration, and it does not say how much weight participants had lost before treatment.
• No comparison group. Both studies are open-label and single-arm. Everyone knew they were treated, and there was no untreated or alternative-treatment group to compare against.
• Small and partly interim. The GLP-1 cohort of HARMONY IN DIVERSITY had 30 people. HALO’s results cover 25 of the 75 participants treated, so the full data are still to come.
• Sponsor-run. Allergan Aesthetics, which makes BOTOX Cosmetic and the JUVÉDERM fillers, ran and reported both studies.
• Satisfaction, not durability. HARMONY’s GLP-1 result was measured 30 days after the toxin, and HALO’s at month 3. Neither tells you how long results hold if weight keeps changing.

None of that makes the findings unimportant. Data from GLP-1 patients specifically is still scarce, and these studies give injectors a reference point. It does mean the practical question for most people is timing: where you are in your program when you start.

What does this mean if you are on a GLP-1 in Portland or Vancouver, WA?

If you are losing weight on a GLP-1 plan and notice facial changes, the evidence so far supports talking with an injector once your dose is stable. At Cosmetiq Medicine, GLP-1 weight loss, Botox and fillers are offered at both the Portland and Vancouver, WA clinics.

Cosmetiq Medicine’s GLP-1 weight loss program in Portland starts from $439 a month and includes a medical intake and check-ins. Because the injectables team works in the same clinics, your weight loss plan and any dermal filler treatment can be timed together instead of in isolation. A few practical points:

• Expression lines and volume are different problems. Botox in Portland is $12 a unit and treats lines caused by muscle movement. Hyaluronic acid filler, at $650 a syringe for lip filler and $750 for other areas, adds volume in the areas each product is FDA-approved for.
• Collagen stimulators are a separate option. Sculptra ($850 a vial) works gradually and was not part of these two studies, so its role is discussed on its own evidence at your visit.
• Source your GLP-1 carefully. The FDA has warned about unapproved and fraudulent GLP-1 products sold for weight loss. Ask any provider where your medication comes from.
• Cost can be spread out. The Glow and Elite med spa memberships lower Botox to $11 or $10 a unit and take a percentage off regular-priced services.

For more background on why faces change during weight loss, see our earlier explainer on GLP-1 facial volume loss, and our report on employers changing GLP-1 coverage for 2027 if you are planning around insurance.

GLP-1 and injectables FAQ

The bottom line

Allergan describes its new data as the first combined neurotoxin and filler results in GLP-1 patients, and participants reported meaningful gains in satisfaction. The studies were small, sponsor-run and limited to people on stable doses, so the most useful step is a consultation that looks at your face and your weight loss timeline together. Our Portland med spa and Vancouver, WA clinic can help you plan both.

This article is for general education and is not medical advice. Treatment suitability is determined at an in-person consultation. Individual results vary.